335 related articles for article (PubMed ID: 23791944)
1. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.
Schmitz KR; Bagchi A; Roovers RC; van Bergen en Henegouwen PM; Ferguson KM
Structure; 2013 Jul; 21(7):1214-24. PubMed ID: 23791944
[TBL] [Abstract][Full Text] [Related]
2. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
Li S; Kussie P; Ferguson KM
Structure; 2008 Feb; 16(2):216-27. PubMed ID: 18275813
[TBL] [Abstract][Full Text] [Related]
4. A molecular view of anti-ErbB monoclonal antibody therapy.
Leahy DJ
Cancer Cell; 2008 Apr; 13(4):291-3. PubMed ID: 18394550
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
Li S; Schmitz KR; Jeffrey PD; Wiltzius JJ; Kussie P; Ferguson KM
Cancer Cell; 2005 Apr; 7(4):301-11. PubMed ID: 15837620
[TBL] [Abstract][Full Text] [Related]
6. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches.
Farasat A; Rahbarizadeh F; Hosseinzadeh G; Sajjadi S; Kamali M; Keihan AH
J Biomol Struct Dyn; 2017 Jun; 35(8):1710-1728. PubMed ID: 27691399
[TBL] [Abstract][Full Text] [Related]
7. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
[TBL] [Abstract][Full Text] [Related]
8. Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
Zeronian MR; Doulkeridou S; van Bergen En Henegouwen PMP; Janssen BJC
BMC Mol Cell Biol; 2022 Mar; 23(1):12. PubMed ID: 35232398
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.
Makabe K; Yokoyama T; Uehara S; Uchikubo-Kamo T; Shirouzu M; Kimura K; Tsumoto K; Asano R; Tanaka Y; Kumagai I
Sci Rep; 2021 Mar; 11(1):5790. PubMed ID: 33707468
[TBL] [Abstract][Full Text] [Related]
10. An integrated computational pipeline for designing high-affinity nanobodies with expanded genetic codes.
Padhi AK; Kumar A; Haruna KI; Sato H; Tamura H; Nagatoishi S; Tsumoto K; Yamaguchi A; Iraha F; Takahashi M; Sakamoto K; Zhang KYJ
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34415295
[TBL] [Abstract][Full Text] [Related]
11. Structural Characterization of Nanobodies during Germline Maturation.
Seidler CA; Kokot J; Fernández-Quintero ML; Liedl KR
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830754
[TBL] [Abstract][Full Text] [Related]
12. Immune response with long-term memory triggered by amorphous aggregates of misfolded anti-EGFR V
Golam Kibria M; Akazawa-Ogawa Y; Hagihara Y; Kuroda Y
Eur J Pharm Biopharm; 2021 Aug; 165():13-21. PubMed ID: 33971271
[TBL] [Abstract][Full Text] [Related]
13. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
14. Crystal structures of a llama VHH antibody BCD090-M2 targeting human ErbB3 receptor.
Eliseev IE; Yudenko AN; Vysochinskaya VV; Svirina AA; Evstratyeva AV; Drozhzhachih MS; Krendeleva EA; Vladimirova AK; Nemankin TA; Ekimova VM; Ulitin AB; Lomovskaya MI; Yakovlev PA; Bukatin AS; Knyazev NA; Moiseenko FV; Chakchir OB
F1000Res; 2018; 7():57. PubMed ID: 30430004
[No Abstract] [Full Text] [Related]
15. The influence of adnectin binding on the extracellular domain of epidermal growth factor receptor.
Iacob RE; Chen G; Ahn J; Houel S; Wei H; Mo J; Tao L; Cohen D; Xie D; Lin Z; Morin PE; Doyle ML; Tymiak AA; Engen JR
J Am Soc Mass Spectrom; 2014 Dec; 25(12):2093-102. PubMed ID: 25223306
[TBL] [Abstract][Full Text] [Related]
16. The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates.
van Lith SAM; van den Brand D; Wallbrecher R; Wübbeke L; van Duijnhoven SMJ; Mäkinen PI; Hoogstad-van Evert JS; Massuger L; Ylä-Herttuala S; Brock R; Leenders WPJ
Eur J Pharm Biopharm; 2018 Mar; 124():63-72. PubMed ID: 29274374
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
18. Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.
Tundidor Y; García-Hernández CP; Pupo A; Cabrera Infante Y; Rojas G
MAbs; 2014; 6(4):1013-25. PubMed ID: 24759767
[TBL] [Abstract][Full Text] [Related]
19. Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance.
Bagchi A; Haidar JN; Eastman SW; Vieth M; Topper M; Iacolina MD; Walker JM; Forest A; Shen Y; Novosiadly RD; Ferguson KM
Mol Cancer Ther; 2018 Feb; 17(2):521-531. PubMed ID: 29158469
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the binding loops configuration and surface adaptation of different crystallized single-domain antibodies in response to various antigens.
Al Qaraghuli MM; Ferro VA
J Mol Recognit; 2017 Apr; 30(4):. PubMed ID: 27862476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
